Insmed (NASDAQ:INSM) CEO William Lewis Sells 13,396 Shares

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 13,396 shares of Insmed stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $44,512,131.15. The trade was a 4.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $0.12 on Wednesday, reaching $148.43. 1,495,878 shares of the company traded hands, compared to its average volume of 2,535,789. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The stock has a market capitalization of $31.66 billion, a PE ratio of -23.98 and a beta of 1.11. The company’s 50 day moving average is $172.50 and its 200-day moving average is $161.37.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Citigroup reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Guggenheim dropped their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Bank of America set a $203.00 price objective on shares of Insmed in a research report on Thursday, December 18th. Finally, Wells Fargo & Company set a $195.00 price objective on Insmed in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $204.24.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. EULAV Asset Management acquired a new stake in Insmed in the 3rd quarter valued at approximately $12,961,000. Resolute Capital Asset Partners LLC bought a new position in shares of Insmed during the 2nd quarter worth approximately $2,748,000. Nisa Investment Advisors LLC increased its holdings in shares of Insmed by 374.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after acquiring an additional 8,261 shares during the last quarter. Keybank National Association OH increased its holdings in shares of Insmed by 76.7% in the third quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock valued at $2,407,000 after purchasing an additional 7,257 shares during the last quarter. Finally, Calamos Advisors LLC raised its holdings in Insmed by 53.4% in the 3rd quarter. Calamos Advisors LLC now owns 35,215 shares of the biopharmaceutical company’s stock valued at $5,071,000 after acquiring an additional 12,263 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.